FREDERICK, Md. -- Drug developers now have access to a shared analytical technology, developed and provided by the Frederick National Laboratory for Cancer Research, that helps fine-tune nanomedicine formulations and overcomes a key hurdle on the path toward Food and Drug Administration approval of effective new therapies and generic versions of nanomedicines. 

Pages